# IDEXX Laboratories Inc. (IDXX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $535.38, market value $42.2 billion.

## Valuation
- **P/E (trailing): 37.6×** (5-yr avg 54.6×, 3-yr avg 48.5×). IDEXX Laboratories Inc. trades at 37.6× trailing earnings, well below its own five-year average of 54.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 32.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.42**. A PEG of 1.42 is in the range usually read as fairly priced for its growth.
- **Price / sales: 9.3×**. Each dollar of revenue is priced at 9.3×.
- **Price / book: 26.2×**. The shares trade at 26.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 26.3×**. Enterprise value is 26.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 3.0%** (5-yr avg 1.6%). Free cash flow equals 3.0% of the market value, above its five-year average of 1.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.7%**. The inverse of the P/E: 2.7% of the price is earned each year.

## Profitability
- **Gross margin: 62.4%**. IDEXX Laboratories Inc. keeps 62.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 32.0%**. 32.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 24.6%**. 24.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 66.0%**. A 66.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 61.5%**. Return on all capital, debt included, is 61.5%: comfortably above what that capital costs.
- **Return on assets: 34.0%**. Each dollar of assets produces 34.0% of profit.

## Growth
- **Revenue growth (1 yr): 10.4%** (3-yr 8.5%/yr, 5-yr 9.7%/yr). Revenue grew 10.4% over the last year, against 9.7% a year compounded over five years.
- **EPS growth (1 yr): 22.6%** (3-yr 17.7%/yr, 5-yr 14.3%/yr). Earnings per share rose 22.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 38.9%/yr**. Free cash flow has compounded at 38.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.28**. Debt is 0.28 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 17.79**. A Z-score of 17.79 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. IDEXX Laboratories Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover IDEXX Laboratories Inc.; the consensus is buy, with an average price target of $698.92 (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -16.4%** (YTD -20.9%, 3-mo -4.8%). The shares are down 16.4% over twelve months including dividends.
- **From 52-week high: -30.5%** (3.2% above the low). Trading 30% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.92** (volatility 32%). Beta of 0.92 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IDXX · Page: https://foliofundamentals.com/stocks/idxx

Not investment advice.